Medical News: ASCO: Abagovomab No Help in Ovarian Cancer - in Meeting Coverage, ASCO from MedPage Today
"Abagovomab maintenance treatment after debulking surgery and
successful platinum and taxane first-line chemotherapy did not prolong
progression-free survival in advanced ovarian cancer," he said in a
late-breaker report given during a packed plenary session.
The invited discussant for the MIMOSA trial, George Coukos, MD, PhD,
professor of gynecologic oncology at the University of Pennsylvania
Philadelphia, suggested that the target of abagovomab – the CA-125
receptor – may not be the best avenue to approach ovarian cancer
recurrence.
"CA-125-targeted immunotherapy based on antibody approaches does not
appear to be a useful clinical strategy," Coucos said. He noted that
oregovomab -- a cousin of abagovomab – also failed to produce positive
results in ovarian cancer.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.